{"filings":[{"id":556796,"accession_number":"0001437749-26-017970","cik":1644903,"company_name":"cbdMD, Inc.","ticker":"YCBD","form_type":"8-K","filed_at":"2026-05-20T21:16:17+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"cbdMD extends warehouse lease through 2031, cuts footprint and annual rent by ~$450k","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Third Amendment to Lease extends term 62 months to Nov 30, 2031 for 40,000 sq ft (down from 80,000).","Monthly base rent starts at $38,000 ($11.40 PSF) with annual increases to $46,233 ($13.87 PSF).","Base rent abated Oct–Nov 2026; additional abatement if wall construction not completed by Dec 31, 2026.","Annual gross rent expense reduction of ~$450,000; net reduction of ~$100,000–$120,000 after sublet rent.","Management states reduced footprint aligns with current and long-term needs and lowers operating expenses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94345,"accession_number":"0001437749-26-012392","cik":1644903,"company_name":"cbdMD, Inc.","ticker":"YCBD","form_type":"8-K","filed_at":"2026-04-15T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"cbdMD grants RSUs to directors and sets annual cash retainers","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Each independent director and non-management employee director receives 1,572 RSUs vesting quarterly through March 31, 2027.","Annual cash retainer of $35,000 for each independent director, payable monthly.","Chairman gets extra $26,500; Audit Committee chair $17,000; Compensation Committee chair $7,000.","Additional committee member retainers: $8,500 for Audit, $4,000 for Compensation Committees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":7870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94344,"accession_number":"0001437749-26-010878","cik":1644903,"company_name":"cbdMD, Inc.","ticker":"YCBD","form_type":"8-K","filed_at":"2026-04-01T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Shareholders approve reverse stock split, dilutive share issuances, and 2025 equity plan at cbdMD annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split from 1:2 to 1:10 approved, board to set ratio within one year.","Approved issuance of >20% of outstanding shares upon conversion of Series B and Series C Preferred and under ELOC with C/M Capital.","2025 Equity Compensation Plan approved with 891,316 initial shares plus 2% annual evergreen (max 300,000/year).","CEO Kennedy receives 445,000 restricted shares under the newly approved plan.","All seven director nominees elected; Cherry Bekaert LLP ratified as auditor for FY2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106624,"accession_number":"0001437749-26-001219","cik":1644903,"company_name":"cbdMD, Inc.","ticker":"YCBD","form_type":"8-K","filed_at":"2026-01-14T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"cbdMD buys Bluebird Botanicals CBD e-commerce assets for 425k shares plus 525k earnout","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired substantially all assets of Gaia Botanicals d/b/a Bluebird Botanicals: brand, domain, trademarks, inventory.","Consideration: 425,000 restricted common shares issued at closing; up to 525,000 earnout shares based on first-year Net Revenues.","Shares issued under Section 4(a)(2) exemption; 180-day lockup with limited dribble-out provisions.","Bluebird operates online CBD marketplace (bluebirdbotanicals.com) selling gummies, oils, soft gels, creams, and pet products.","cbdMD assumed certain liabilities; includes repayment of a $200,000 member loan prior to closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122953,"accession_number":"0001437749-25-037156","cik":1644903,"company_name":"cbdMD, Inc.","ticker":"YCBD","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"cbdMD regains NYSE American compliance; BC indicator removed Dec 8, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received NYSE American letter Dec 5, 2025 confirming compliance with Sections 1003(a)(i) and (ii).","Previously identified deficiencies resolved; BC indicator removed effective Dec 8, 2025.","CEO credits May Series A Preferred share conversion and September capital raise as key to compliance.","Company remains subject to continued listing monitoring going forward."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122952,"accession_number":"0001437749-25-036497","cik":1644903,"company_name":"cbdMD, Inc.","ticker":"YCBD","form_type":"8-K","filed_at":"2025-11-28T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"cbdMD enters new 3-year CEO employment agreement with $340k base salary, 445k restricted share award subject to approval","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO/CFO T. Ronan Kennedy signs 3-year term; base salary of $340,000 per year.","Granted 445,000 restricted shares under new 2025 Equity Plan; vesting conditioned on shareholder approval.","Board approved 2025 Equity Compensation Plan reserving 891,316 shares, with evergreen formula up to 2% annually.","Quarterly performance bonus target up to $140k annually, with potential escalator to $175k based on positive EBITDA.","Severance: if terminated without cause, receives base salary for balance of term (minimum 12 months) and full equity acceleration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122951,"accession_number":"0001437749-25-036342","cik":1644903,"company_name":"cbdMD, Inc.","ticker":"YCBD","form_type":"8-K","filed_at":"2025-11-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"cbdMD Q4 net sales up 3-5% YoY; FY net loss improves to ~$2M from $3.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales for fiscal 2025 expected $19.1–19.3M vs $19.5M prior year.","Q4 net sales expected $4.7–4.9M, up 3-5% from $4.6M in Q4 2024.","Net loss for fiscal 2025 improved to $1.9–2.1M from $3.7M in fiscal 2024.","CEO cites disciplined cost management and positive sequential revenue growth.","Full earnings call scheduled for mid-December 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":19190468.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122950,"accession_number":"0001437749-25-030537","cik":1644903,"company_name":"cbdMD, Inc.","ticker":"YCBD","form_type":"8-K","filed_at":"2025-10-06T23:59:59+00:00","items":["1.01","3.02","5.03","9.01"],"status":"ready","headline":"cbdMD raises $1.7M gross via Series B Convertible Preferred, net $1.5M for working capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 1,700,000 shares of Series B Convertible Preferred to four institutional investors for $1.7M gross proceeds.","Net proceeds of $1.5M after expenses; funds used for working capital.","Each share convertible into common at $1.00 per share, subject to anti-dilution and Alternative Conversion.","Series B Preferred accrues 10% annual dividends payable quarterly in shares or cash, senior liquidation preference.","Holders have no voting rights; beneficial ownership limited to 4.99% of common stock outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157237,"accession_number":"0001437749-25-017864","cik":1644903,"company_name":"cbdMD, Inc.","ticker":"YCBD","form_type":"8-K","filed_at":"2025-05-20T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"cbdMD board grants RSUs to directors, sets annual cash retainers","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Each independent director and non-management employee director receives 1,572 RSUs.","RSUs vest quarterly through March 31, 2026; granted under 2015 and 2021 equity plans.","Annual cash retainer of $35,000 per independent director; additional chair and committee fees.","Chairman receives extra $26,500; Audit Committee chair $17,000; other committee chairs $7,000.","Audit committee members (non-chair) receive $8,500; other committee members $4,000."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":7870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157236,"accession_number":"0001437749-25-015119","cik":1644903,"company_name":"cbdMD, Inc.","ticker":"YCBD","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"cbdMD converts all Series A Preferred to common, effects 1-for-8 reverse stock split","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 5,000,000 outstanding 8% Series A Preferred shares automatically converted into 65,000,000 common shares on May 6, 2025.","Immediately after conversion, a 1-for-8 reverse stock split of common stock was effected; adjusted trading began May 7 on NYSE American.","No fractional shares issued; shareholders entitled to fractional shares receive one whole share.","Preferred dividends ceased accruing as of May 6, 2025; preferred stock stopped trading on NYSE American.","Shareholders approved both the conversion and reverse split at the April 10, 2025 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157235,"accession_number":"0001437749-25-011788","cik":1644903,"company_name":"cbdMD, Inc.","ticker":"YCBD","form_type":"8-K","filed_at":"2025-04-11T23:59:59+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"cbdMD shareholders approve automatic conversion of Series A Preferred Stock into common at 13:1","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved automatic conversion of each Series A Preferred share into 13 common shares, eliminating $6.7M in accrued dividends and $4M annual dividend obligations.","Seven directors elected: Bakari Sellers, William F. Raines III, Scott G. Stephen, Dr. Sybil Swift, T. Ronan Kennedy, Jeffrey Porter, Kevin Roe.","Shareholders ratified Cherry Bekaert LLP as independent auditor for fiscal year ending Sept 30, 2025.","Shareholders authorized reverse stock split at a ratio from 1:3 to 1:10, at Board's discretion within one year.","CEO Ronan Kennedy stated conversion will strengthen balance sheet and enable strategic activity including M&A."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":7870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175607,"accession_number":"0001437749-25-001223","cik":1644903,"company_name":"cbdMD, Inc.","ticker":"YCBD","form_type":"8-K","filed_at":"2025-01-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"cbdMD fully converts remaining $56K senior secured notes to equity, now debt-free","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Remaining $56,000 Senior Secured Convertible Notes converted to common stock on Jan 14, 2025.","Company now debt-free excluding accounts payable; strengthened cash reserves and balance sheet.","Shares outstanding post-conversion: 6,262,833 common stock as of Jan 14, 2025.","CEO Ronan Kennedy cites enhanced flexibility to allocate capital for profitable revenue growth.","Notes converted ahead of maturity, eliminating debt and improving financial position."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175606,"accession_number":"0001437749-25-000768","cik":1644903,"company_name":"cbdMD, Inc.","ticker":"YCBD","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"cbdMD reduces convertible note debt to $56K; issued 609K shares; Q1 cash ~$2.1M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Convertible note principal reduced to ~$56,000 as holders converted ~$309,000 principal plus accrued interest.","Issued 609,717 common shares in January 2025 to satisfy conversion requests.","Total outstanding common shares now 6,152,841 as of Jan 8, 2025.","CEO reports fiscal Q1 end cash and cash equivalents of approximately $2.1 million.","Company frames debt reduction and cash position as improving balance sheet and liquidity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175605,"accession_number":"0001437749-25-000291","cik":1644903,"company_name":"cbdMD, Inc.","ticker":"YCBD","form_type":"8-K","filed_at":"2025-01-03T23:59:59+00:00","items":["3.01","8.01","9.01"],"status":"ready","headline":"cbdMD receives additional NYSE American noncompliance notice for equity under $2M","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stockholders' equity $1,963,417 as of Sep 30, 2024, below $2M threshold; losses in 4 of 5 recent fiscal years.","Plan accepted Aug 20, 2024 for prior equity deficiency; new deadline Dec 5, 2025 to regain compliance.","Company may seek shareholder approval to convert $4.67M Preferred Stock liability (incl. accrued dividends) into common equity.","Cash consumption reduced to $0.7M in fiscal 2024 from $4.9M in fiscal 2023; trading continues with \".BC\" designation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192553,"accession_number":"0001437749-24-038295","cik":1644903,"company_name":"cbdMD, Inc.","ticker":"YCBD","form_type":"8-K","filed_at":"2024-12-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"cbdMD appoints CEO/CFO Ronan Kennedy to Board, expanding to 5 members","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Expanded Board from 4 to 5; Kennedy appointed effective Dec 18/19, 2024.","Kennedy will not receive additional compensation for board service.","Three of five Board members meet independence standards; Kennedy is not independent.","Kennedy's term expires at the 2025 annual shareholder meeting; he will not serve on committees.","Press release highlights Kennedy's role in cost optimization and cash position improvement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":7870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192552,"accession_number":"0001437749-24-036298","cik":1644903,"company_name":"cbdMD, Inc.","ticker":"YCBD","form_type":"8-K","filed_at":"2024-11-27T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"cbdMD extends warehouse lease through Sep 2026, discloses share issuance on debt conversion","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease amended: 19-month extension from Mar 1, 2025 to Sep 30, 2026; monthly base rent $65K first year, $67.6K second year.","No further extension rights; subleases approved for 24,000 SF and 8,300 SF.","As of Nov 25, 2024, ~4.47M common shares outstanding.","Issued 627,011 shares during Sept-Nov 2024 upon partial conversion of Senior Secured Convertible Notes.","Lease extension avoids relocation costs and provides time to find long-term facility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":7870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209015,"accession_number":"0001437749-24-028132","cik":1644903,"company_name":"cbdMD, Inc.","ticker":"YCBD","form_type":"8-K/A","filed_at":"2024-08-30T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"cbdMD gets NYSE American plan acceptance for listing; equity at $3.1M, deadline Dec 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["NYSE American accepted cbdMD's plan to regain compliance; plan period through Dec 5, 2025.","Company had stockholders' equity of $3.1M as of Mar 31, 2024, below $4M requirement.","Correction: Original 8-K erroneously stated stockholders' deficit; correct figure is equity of $3.1M.","Company subject to quarterly review; failure to progress could lead to delisting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209020,"accession_number":"0001437749-24-027959","cik":1644903,"company_name":"cbdMD, Inc.","ticker":"YCBD","form_type":"8-K","filed_at":"2024-08-29T23:59:59+00:00","items":["1.01","3.02"],"status":"ready","headline":"cbdMD acquires 'CBD MD' trademark from Majik Medicine for cash/stock; settles litigation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Paid $100k cash on closing; will pay $50k annually for 4 years ($300k total) and issued 75k shares of common stock (50k more in year 2).","Entered 5-year consulting agreement with Majik; 15% commission on net sales increase from new wholesale customer base of licensed practitioners.","Amendment to existing convertible notes and security agreement allows pledge of new trademark as permitted lien and payments as permitted indebtedness.","Majik appointed board member William Raines III as proxy for the initial shares for 12 months.","Company expects mark enhances IP portfolio and removes TTAB procedural impediments, avoiding continued litigation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209019,"accession_number":"0001437749-24-027762","cik":1644903,"company_name":"cbdMD, Inc.","ticker":"YCBD","form_type":"8-K","filed_at":"2024-08-26T23:59:59+00:00","items":["3.01","8.01","9.01"],"status":"ready","headline":"cbdMD receives NYSE American acceptance of compliance plan; faces Dec 5, 2025 deadline","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stockholders' deficit of $3.1M as of March 31, 2024; non-compliance with $4M equity requirement.","Plan period through December 5, 2025; quarterly reviews to monitor progress.","If plan fails, NYSE American may initiate delisting proceedings; common and preferred shares remain listed during period.","CEO notes plan acceptance is step to address capital structure and re-engage preferred shareholders on accrued dividend.","Prior non-compliance notice received June 5, 2024 under Section 1003(a)(ii) for losses in three of four recent fiscal years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209014,"accession_number":"0001437749-24-027247","cik":1644903,"company_name":"cbdMD, Inc.","ticker":"YCBD","form_type":"8-K/A","filed_at":"2024-08-19T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"cbdMD settles former office lease, expects ~$780K in total gains","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Paid $255K to satisfy all past due obligations under former lease; mutual release executed.","Anticipates ~$550K gain on settlement of accrued rent, interest, and penalties.","Additional ~$230K non-cash gain from termination of original lease (corrected from prior error).","Company has no further obligations to landlord under any agreements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209018,"accession_number":"0001437749-24-027041","cik":1644903,"company_name":"cbdMD, Inc.","ticker":"YCBD","form_type":"8-K","filed_at":"2024-08-15T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"cbdMD settles former lease with $255K payment, records $550K gain","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Made $255,000 payment on Aug 15, 2024 to satisfy all past due lease amounts; mutual release executed.","Anticipates $550,000 gain on settlement of accrued past due rent, interest, and penalties.","$230,000 non-cash expense from elimination of right-of-use asset/liability partially offsets gain.","No further obligations to landlord under former lease agreements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209017,"accession_number":"0001437749-24-023092","cik":1644903,"company_name":"cbdMD, Inc.","ticker":"YCBD","form_type":"8-K","filed_at":"2024-07-19T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"cbdMD reports 3,763,433 shares outstanding after note conversions; $1.08M notes balance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["As of July 19, 2024, common shares outstanding: 3,763,433 after reconciling partial conversions of 8% Senior Secured Convertible Promissory Notes.","Aggregate principal balance of the Notes outstanding: $1,076,963.","Update reflects conversion activity on the Notes, with no other material corporate events disclosed.","Filing made under Item 8.01 Other Events, providing transparency on current capital structure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":7870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209016,"accession_number":"0001437749-24-022816","cik":1644903,"company_name":"cbdMD, Inc.","ticker":"YCBD","form_type":"8-K","filed_at":"2024-07-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"cbdMD submits NYSE American compliance plan; expects response in August 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received NYSE American non-compliance notice on June 5, 2024 for continued listing standards.","Submitted a compliance plan by the July 5, 2024 deadline to regain compliance by December 5, 2025.","Expects a response from NYSE American in August 2024 regarding the plan's acceptance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":7870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226863,"accession_number":"0001437749-24-019721","cik":1644903,"company_name":"cbdMD, Inc.","ticker":"YCBD","form_type":"8-K","filed_at":"2024-06-10T23:59:59+00:00","items":["3.01","8.01","9.01"],"status":"ready","headline":"cbdMD receives NYSE American delisting notice for equity shortfall; must submit compliance plan by July 5, 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stockholders' equity was $3.1M as of March 31, 2024, below $4M minimum required by Section 1003(a)(ii).","Company reported losses in three of four most recent fiscal years ended Sep 30, 2023.","Must submit compliance plan by July 5, 2024; has until Dec 5, 2025 to regain compliance or face delisting.","Seeking shareholder approval to convert Preferred Stock and $2.7M accrued dividend into equity to boost equity.","Trading continues under symbols with '.BC' designation for 'below compliance'; no immediate impact on operations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":7870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226862,"accession_number":"0001437749-24-010629","cik":1644903,"company_name":"cbdMD, Inc.","ticker":"YCBD","form_type":"8-K","filed_at":"2024-04-02T23:59:59+00:00","items":["5.02","5.07","8.01"],"status":"ready","headline":"cbdMD appoints new CEO/CFO, Chairman, and CAO; shareholder vote rejects Series A automatic conversion","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Bradley Whitford appointed Chief Accounting Officer, Treasurer, Secretary; annual base salary $200,000.","T. Ronan Kennedy named CEO and CFO; Scott G. Stephen appointed Chairman.","Proposal to amend Series A Preferred Certificate of Designation for automatic conversion into common stock was not approved by shareholders.","Board members receive RSUs for 4,000 shares vesting quarterly and option for 2,000 shares vesting immediately.","All other six proposals at annual meeting approved, including director elections and auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245808,"accession_number":"0001437749-24-008153","cik":1644903,"company_name":"cbdMD, Inc.","ticker":"YCBD","form_type":"8-K","filed_at":"2024-03-18T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"cbdMD enters forbearance on sublease default, moves executive offices","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Behind on rent since Sep 2023; default notice and summary ejectment filed Feb 2024.","Forbearance requires $80k upfront plus four monthly payments of $40k to HSKL.","Granted HSKL license to use Red Oak Facilities through July 31, 2024; sublease ends.","Executive offices moved to 2101 Westinghouse Blvd, existing warehouse location.","Breach of forbearance lets HSKL immediately pursue all remedies under sublease."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245807,"accession_number":"0001437749-24-006177","cik":1644903,"company_name":"cbdMD, Inc.","ticker":"YCBD","form_type":"8-K","filed_at":"2024-03-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"cbdMD posts updated investor deck for non-deal roadshows; no material new info","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Executives to use new investor presentation in non-deal roadshows starting Feb 29, 2024.","Presentation available on cbdMD website under 'Investor Presentations' section.","Filing text does not disclose any specific financial or operational changes.","Investor deck content not provided in text; no new figures or guidance available."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":7870000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}